Metrics to compare | LXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLXRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −15.0x | −2.0x | −0.4x | |
PEG Ratio | −0.29 | −0.02 | 0.00 | |
Price/Book | 5.2x | 3.8x | 2.6x | |
Price / LTM Sales | 22.0x | 28.2x | 3.1x | |
Upside (Analyst Target) | 87.2% | 305.2% | 55.6% | |
Fair Value Upside | Unlock | 9.7% | 7.8% | Unlock |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.